Natera registered 68,023 shares for potential resale by unnamed, non-affiliated selling stockholders. The total includes 45,533 closing shares issued on or about November 10, 2026 and an estimated 22,490 additional shares; Natera receives no proceeds.
NTRA · Natera, Inc.
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Up next
Latest documents
Natera targets $6 billion in revenue by 2029, using $14.50 Signatera ASP versus $12.90 today as an illustrative path. Solomon became CEO immediately, with operating and commercial structures unchanged.
Natera CEO Solomon Moshkevich targets $6 billion in revenue for 2029; Signatera is expected to generate a little over a billion this year, with the fine study readout expected in the back half of next year.
Natera says Solomon will succeed Steve as CEO, raising full-year 2026 revenue guidance to $3 billion $5 million-$3 billion $35 million and targeting $6 billion in 2029.
Natera reported that total revenues increased $201.8 million, or 34.1%, in the three months ended September 30, 2026, while net loss narrowed 31.6%. For the nine months, revenue was $2,243.4 million and net loss was $212.0 million.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
AI Brief
Q3 FY26 earnings call · Nov 5, 2026TL;DR. Q3 revenue grew 34.1%, clinical MRD volume grew more than 56%, and management raised 2026 revenue guidance by $140 million at the midpoint. Underlying gross margin improved, cash increased, the net loss narrowed, HCC coverage was granted, Japan commercialization remained on track, pharma revenue accelerated, and management set a $6 billion 2029 revenue target alongside early-detection milestones.
- + Pharma revenue accelerated sharply, with first-nine-month revenue already up roughly 70% versus all of 2025. new
- − Natera remained unprofitable, reporting a $59.9 million net loss in Q3 2026. new
- − Reported gross margin declined 24 basis points year over year to 64.7%. new
- − Total operating expenses increased 19.5% year over year because of headcount growth and higher clinical-trial spending. new
- − Early cancer detection is consuming more than $100 million while generating no revenue. new
- − Higher COGS from newer products such as Fetal Focus and Signatera Genome may create short-term gross-margin pressure. new
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders SellIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| clinical MRD oncology tests | 283K | Q2 2026 | — |
| Oncology tests processed | 296,700 | Q2 2026 | — |
| Tests accessioned | 1,030,100 | Q2 2026 | — |
| Tests processed | 1,043,900 | Q2 2026 | — |
| Tests reported | 985,500 | Q2 2026 | — |
| Tests reported in our laboratory | 972,000 | Q2 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Diagnostics & Research — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
NTRA
this stock
Natera, Inc.
|
$41.83B | +25.9% | -2.8% | — | 4.2% |
|
TMO
Thermo Fisher Scientific Inc.
|
$256.15B | +19.3% | +14.5% | 36.5 | 1.3% |
|
DHR
Danaher Corp
|
$161.75B | +0.4% | +8.5% | 37.6 | 1.2% |
|
IDXX
Idexx Laboratories Inc
|
$55.20B | +3.6% | +10.4% | 47.2 | 3.0% |
|
A
Agilent Technologies, Inc.
|
$48.75B | +27.1% | +6.4% | 34.0 | 1.7% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 12, 2026
- This year
- 24
Natera registered 68,023 shares for potential resale by unnamed, non-affiliated selling stockholders. The total includes 45,533 closing shares issued on or about November 10, 2026 and an estimated 22,490 additional shares; Natera receives no proceeds.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| NTRA | -10.0% | -27.8% | +42.0% | -30.4% | +25.9% |
| SPY | -1.7% | -3.5% | -1.4% | -2.1% | +8.5% |
| vs SPY | -8.3% | -24.3% | +43.4% | -28.3% | +17.4% |